Media stories about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.4256806852749 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $6.51 on Friday. The firm has a market cap of $334.71, a PE ratio of -2.27 and a beta of 2.51. Tetraphase Pharmaceuticals has a fifty-two week low of $3.57 and a fifty-two week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.63). The company had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The firm’s quarterly revenue was up 355.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.58) EPS. analysts anticipate that Tetraphase Pharmaceuticals will post -2.88 EPS for the current year.

A number of brokerages recently weighed in on TTPH. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a report on Saturday, September 23rd. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th. BMO Capital Markets boosted their price target on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, October 4th. Finally, ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $15.15.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of the company’s stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at $52,762.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director L Patrick Gage acquired 3,880 shares of the company’s stock in a transaction on Wednesday, November 29th. The shares were acquired at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the acquisition, the director now owns 38,880 shares of the company’s stock, valued at $250,776. The disclosure for this purchase can be found here. 5.50% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This report was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Insider Buying and Selling by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with's FREE daily email newsletter.